Differences in quality of life between genders in acromegaly

Daniel Ballesteros-Herrera1 | Paulina Briseño-Hernández2 | Rodrigo Pérez-Esparza3* | Lesly A. Portocarrero-Ortiz2,4

Abstract

Objective: To study the impact of secondary mental disorders in patients affected with acromegaly and correlate them with quality of life (QoL) and disease status.

Design: An observational transversal descriptive and comparative study that evaluates QoL's impact due to secondary mental disorders in affected Mexicans with acromegaly using AcroQoL and SF-36 instruments. Correlation of the results with the disease's biochemical status was performed. According to Beck's scales, anxiety and depression analyses evaluate QoL's impact, and its gender variability is described.

Results: Eighty-five patients with diagnoses of acromegaly were included. The mean age was 43.18 years, 47 being women (55.29%). The mean age at diagnosis was 37.95 years, with no difference between men and women. AcroQoL and SF-36 global and sub-domain scores differed significantly between men and women, the latter having lower global and individual sub-domain scores. The mean score of QoL, according to AcroQoL, is 59.40. In women, the mean values are less (55.13) than men (64.68), \( p = 0.021 \). The sub-domain analyses' scores in physical, appearance and social relationships were less in women (53.21; 47.34; 62.32) than men (62.68; 56.76; 73.87) \( p = 0.044, 0.069 \) and 0.013, respectively. Higher Beck's Depression Inventory (BDI) and Beck's Anxiety Inventory (BAI) scores correlated with lower QoL as assessed by global and individual sub-domain scores. Women presented significantly higher BDI and BAI mean scores when compared to men regardless of their biochemical status. Anxiety (\( p = 0.027 \)) and depression (\( p < 0.001 \)) severity were higher in women compared to men.

Conclusion: Correlations between female gender, depression/anxiety scores and QoL require further validation. There is much to be routinely done to improve secondary psychopathology in patients affected by this disease. The need for mental status screening at diagnosis should be emphasized to identify secondary mental illnesses to improve QoL with its treatment.

KEYWORDS
acromegaly, anxiety, depression, gender, quality of life

1Department of Neurosurgery, Instituto Nacional de Neurología y Neurocirugía, MVS, Mexico City, Mexico
2Universidad Nacional Autónoma de México, Mexico City, Mexico
3Department of Neuropsychiatry, INNN, Mexico City, Mexico
4Department of Neuroendocrinology, INNN, Mexico City, Mexico

Correspondence
Lesly A. Portocarrero-Ortiz, Department of Neuroendocrinology, Instituto Nacional de Neurología y Neurocirugía MVS, Insurgentes Sur 3877, La Fama, Tlalpan 14269, Mexico City, Mexico. Email: portocarrero.lesly@gmail.com

†Deceased.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
INTRODUCTION

Acromegaly is a rare disease caused by the hypersecretion of growth hormone (GH) and a secondary insulin-like factor 1 (IGF-1) secretion, in most cases, due to a secreting presence of pituitary adenoma. Prevalence has been estimated, ranging between 2.8 and 13.7 cases per 100,000 population, affecting males and females almost equally. The Mexican Acromegaly Registry (MAR) has registered more than 2,000 cases of the disease, estimating a regional prevalence of 18 cases per million population. A greater prevalence in women compared to men, commonly associated with glucose abnormalities and hypertension.

Health-related quality of life (QoL) has been used as an outcome in clinical practice that assesses patients’ perception of their well-being and functioning. Although numerous QoL measurement instruments have been developed, the Acromegaly Quality of Life Questionnaire (AcroQoL) addresses some specific items regarding disease progression and treatment outcomes. Several factors have been identified as impacting QoL in acromegaly, including depression, body mass index (BMI), body image, general psychopathology, pain, comorbidities and type of treatment. Biochemical markers of treatment outcomes have not been consistently associated with a change in QoL scores. Overall, the results of most studies regarding predictors of QoL in acromegaly are ambiguous or insufficient.

This study aimed to describe the QoL in treated patients with acromegaly in the Mexican National Institute of Neurology and Neurosurgery.

MATERIAL AND METHODS

An observational transversal descriptive and comparative study that included patients with acromegaly. The evaluation of QoL with AcroQoL, SF-36 and secondary psychopathology with BDI and BAI scales was performed with the patient’s previous consent. Results were correlated with gender, disease’s biochemical status, comorbidities, tumoral size and type of treatment.

Patients

Patients were older than 18 years with a diagnosis of acromegaly based on the Second Mexican Consensus (age- and sex-adjusted IGF-1 levels in combination with GH nadir during an oral glucose tolerance test with cut-offs of >0.5 ng/dL), who were attending follow-up in the Neuroendocrinology clinic of the INNN from 2011 to 2014. All patients were included regardless of age at diagnosis.

Patients were divided into two groups: biochemically active and controlled (defined as a glucose-suppressed GH below <0.5 ng/mL and a normal IGF-1).

Quality of life was assessed using the AcroQoL and the 36-Item Short Form Survey (SF-36). Additionally, Beck’s Depression Inventory (BDI) and Beck’s Anxiety Inventory (BAI) were filled out by the patients to evaluate these psychiatric symptom domains.

AcroQoL consists of 22 items, each punctuated with a maximum of 5 points. Results are reported from 22 (worst QoL) to 110 (best QoL). To interpret the results in a range of 0–100, standardization with a mathematical adjustment was performed (Y = ([X-min] x 100) / max-min)).

SF-36 comprises 36 items that evaluate 8 dimensions: physical functioning, physical role, pain, general health, vitality, social functioning, emotional and mental health. The range for each dimension is evaluated from 0 to 100. Depending on the number of categories, each answer is worth a different percentage to complete a maximum of 100 (example=3 categories=0–50–100). The average of each category gives the result of each dimension. The average of all dimensions gives the final result. The closest to 100 is the best, and 0 is the worst.

BDI consists of 21 items, each punctuated with a maximum of 3 points, from 0 (best) to 63 points (worst). According to results, patients are classified in minimum (0–9), mild (10–16), moderate (17–29), and severe (30–36). As same as BDI, BAI is punctuated from 0 to 3 for every 21 items, classifying patients, as stated earlier.

Sociodemographic and disease-related variables were acquired using the medical records.

Results were presented as means (SDs). Normality was examined using the Shapiro–Wilk test, and Spearman’s test assessed the association of clinical variables with AcroQoL, SF-36, BDI and BAI scores.

The present study was approved by the Ethics and Scientific Committees of the National Institute of Neurology and Neurosurgery (INNN) in Mexico City. Written informed consent of all subjects was obtained before participation.

RESULTS

Eighty-five patients with a diagnosis of acromegaly were included. The mean age was 43.18 years ±10.79, 47 being women (55.29%). The mean age at diagnosis was 37.95 ± 13.59 years, with no difference between men and women.

FIGURE 1 Correlation between AcroQol Global Score and patient’s disease status. A significant lower total score in females compared to males in any status
3.1 | QoL and sociodemographic characteristics

AcroQoL and SF-36 global and sub-domain scores (AcroQoL Physical, AcroQoL Relationships; SF-36 Physical functioning, SF-36 Social functioning, SF-36 Emotional well-being, SF-36 Energy/fatigue and SF-36 Pain) differed significantly between men and women (Figure 1), the latter having lower global and individual sub-domain scores. Mean QoL value, according to AcroQoL, is 59.40. In women, the mean values are less (55.13) than men (64.68) \( p = 0.021 \). In the sub-domain analyses, physical, appearance and social relationships mean scores in women were less (53.21; 47.34; 62.32), compared to men (62.68; 56.76; 73.87) \( p = 0.044, 0.069 \) and \( 0.013 \), respectively. Women were also more commonly unemployed (57.45%; \( p = 0.002 \)), correlating with lower physical AcroQoL scores (\( p = 0.043 \)). Age, marital status and years of education did not differ between sex and were not associated with QoL scores.

3.2 | QoL and clinical characteristics

At diagnosis, age was 44.51 ± 10.91 years for women and 41.53 ± 10.55 years for men, with no difference between genders – age was not associated with different QoL scores. Tumour size was available for 80 patients. 17 were microadenomas and 63 macroadenomas. There was no relation between tumour size and QoL scores.

3.3 | QoL and biochemical markers

Considering GH and IGF-1 cut-off values to define cured, active, or discordant acromegaly, only cured acromegaly was associated with global AcroQoL scores (\( p = 0.05 \)). Cured patients presented a better score in vitality and pain items of SF-36 compared with active patients (\( p = 0.060 \), and \( p = 0.057 \)) with no statistical significance.

3.4 | QoL and mental health

When comparing BDI (16.40 ± 10.35 vs. 9.34 ± 6.98, \( p = 0.001 \)) and BAI (21.19 ± 12.36 vs. 10.95 ± 7.87) scores between women and men, higher scores correlated with lower QoL as assessed by global, and all sub-domain scores in AcroQoL (\( p =<0.001 \)) regardless of their biochemical status (Table 1). When assessing severity, 40.43% of women presented moderate to severe depression, compared to 15.79% in men (\( p < 0.001 \)). Moderate to severe anxiety was present in 68.83% of women, compared to 21.05% in men (\( p = 0.027 \)).

3.5 | QoL and comorbidity

Comorbidity information was available for 81 patients of the total sample. Diabetes, glucose abnormalities, hypothyroidism, hypogonadism, hypopituitarism, hypocortisolism, hypertension and dyslipidaemia were considered important associated comorbidities. Of the 81 patients, 31 were comorbidity free; 11 presented 1; 14 presented

| Scale and sub-domains | Total Sample | Men | Women | \( p \) |
|-----------------------|-------------|-----|-------|------|
| AcroQoL Global        | 59.40 ± 19.06 | 64.68 ± 19.15 | 55.13 ± 18.07 | 0.021* |
| AcroQoL Physical      | 57.45 ± 21.62 | 62.68 ± 22.52 | 53.21 ± 20.13 | 0.044* |
| AcroQoL Body Image    | 51.55 ± 23.76 | 56.76 ± 22.51 | 47.34 ± 24.14 | 0.069 |
| AcroQoL Relationships | 67.48 ± 21.55 | 73.87 ± 22.19 | 62.32 ± 19.77 | 0.013* |
| SF-36 Physical Functioning | 66.54 ± 25.15 | 73.18 ± 24.85 | 61.17 ± 24.34 | 0.017* |
| SF-36 Social Functioning | 71.88 ± 25.84 | 81.79 ± 19.83 | 63.87 ± 27.49 | 0.003* |
| SF-36 Physical Limitations | 47.80 ± 42.84 | 54.29 ± 44.68 | 42.55 ± 41.02 | 0.309 |
| SF-36 Emotional Limitations | 58.16 ± 40.34 | 61.63 ± 38.60 | 55.36 ± 41.90 | 0.477 |
| SF-36 Emotional Well-being | 65.74 ± 21.70 | 73.47 ± 16.04 | 59.49 ± 23.75 | 0.003* |
| SF-36 Energy/fatigue | 57.87 ± 20.27 | 64.21 ± 20.88 | 52.74 ± 18.43 | 0.009* |
| SF-36 Pain | 65.72 ± 26.57 | 73.08 ± 24.03 | 59.77 ± 27.26 | 0.021* |
| SF-36 General Health | 53.41 ± 21.65 | 56.84 ± 20.61 | 50.64 ± 22.28 | 0.191 |
| BDI                   | 13.25 ± 9.62 | 9.34 ± 6.98 | 16.40 ± 10.35 | 0.001* |
| BAI                   | 16.61 ± 11.71 | 10.95 ± 7.87 | 21.19 ± 12.36 | 0.001* |

Abbreviations: 36-Item Short Form Survey; Beck’s Depression Inventory; AcroQoL, Acromegaly Quality of Life Questionnaire; BAI, Beck’s Anxiety Inventory.

*Significant ‘\( p \)’ values.
We found a marked prevalence of lower scores in women, related to higher anxiety and depression scores, and markedly lower AcroQoL global scores with statistically significant differences in appearance and physical effects consistent with the previously reported English literature.10 Matta et al. in 2008 evaluated QoL using SF-36 and found that the most affected item was physical appearance. In our results, appearance was the most affected with a score of 47.34 ± 24.14 in women and 62.88 ± 22.52 in men despite biochemical status. The less affected was personal relationships with a score of 62.32 ± 19.77, following the presented study. SF-36 results displayed differences between cured and non-cured patients, being the latter the ones with lower scores. We found no statistically significant differences in physical performance, and general health status, like Van der Klau study.19 One of the latest studies studying the effects of acromegaly in QoL by Solomon et al.20 reported executive function compromise in an observational case–control study.

Psychologic morbidity is present in a significant percentage of patients with acromegaly, especially women. This association found between QoL and female gender has been reported in other previous studies, with no difference between treatment modalities.21–23 Nonetheless, no consensus has been reached. In Mexico, Garduño24 highlighted that women had worse global scores with no correlation between GH levels, tumoral size, disease status and QoL. Our study found lower scores in all sub-domains in females compared to males with a statistically significant difference. Our least affected item was interpersonal relationships.

Female patients suffer depression and lower self-esteem due to the morphologic changes derived from the disease.25 Another aspect that seems to contribute is fatigue that can affect daily activities and work performance. During our correlation of depressive symptoms with the QoL questionnaires,26 negative coefficients reflected a greater number of depressive symptoms indicative of QoL deterioration. The detriment of QoL is not only explained by biochemical disease status but also by secondary psychopathology. Our findings are similar to Geraedts, reaffirming that evaluation of depressive and anxious symptoms, which are modifiable, would improve the patients’ management, and therefore QoL.5,6,21,26 Women appear to have a higher severity of psychiatric disorders than men. Probably because of their rigorous self-assessment and self-approbation. We also consider that Mexican idiosyncrasy could influence these results. Nonetheless, this has not been studied extensively. No previous reports have assessed anxiety levels as our study, an important matter to our psychologic assessment consideration.

The principal study limitation is its transversal nature. We also had one evaluation after treatment, where the only thing we could compare is QoL as a group and between cured and non-cured during the evaluation. We consider our sample as representative of our population. Nonetheless, it is convenient to perform these questionnaires to every patient diagnosed with acromegaly from the first evaluation.
and during follow-up. Longitudinal studies during the course of the disease are needed to solve these matters and clarify what we know about secondary psychopathology.

6 | CONCLUSION

Correlations between female gender, depression/anxiety scores and QoL require further validation with multi-centric studies. Secondary psychopathology should be included during the initial assessment of patients with acromegaly. It should emphasize the need for mental status screening at acromegaly diagnosis, especially in women, because of the high incidence and severity of secondary mental illnesses in this particular population. Confirming the high negative impact, it confers to QoL.

ACKNOWLEDGEMENTS

To all the people involved in this study that permitted the collection of data and its analysis. Dedicated to Dr. Perez Esparza, who was vital in making this article and is no longer with us (†).

CONFLICT OF INTEREST

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. No conflict of interest could be perceived as prejudicing the impartiality of the research reported.

AUTHOR CONTRIBUTIONS

Lesly A. Portocarrero-Ortiz contributed to idea conception, supervision in manuscript elaboration and participated in the discussion. Daniel Ballesteros-Herrera contributed to redaction of the manuscript, translation to English, participated in the discussion and publication logistics. Paulina Briseño-Hernández contributed to questionnaire application. Rodrigo Pérez-Esparza contributed to statistical analysis and participated in the discussion.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions under the Mexican law that protects personal data.

ORCID

Daniel Ballesteros-Herrera https://orcid.org/0000-0003-3837-8765
Lesly A. Portocarrero-Ortiz https://orcid.org/0000-0003-2051-4861

REFERENCES

1. Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22-32.
2. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4-9.
3. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101(11):3997-4004.
4. Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf). 2002;57(2):251-258.
5. Geraedts VJ, Andela CD, Stalla GK, et al. Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol. 2017;8:40.
6. Crespo I, Valassi E, Webb SM. Update on quality of life in patients with acromegaly. Pituitary. 2017;20(1):185-188.
7. Wolters T, Roerink S, Sterenborg R, et al. The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur J Endocrinol. 2020;182(3):319-331.
8. Arellano S, Aguilar P, Domínguez B, et al. Segundo Consenso Nacional de Acromegalia: Recomendaciones para su diagnóstico, tratamiento y seguimiento. Rev Endocrinol Nutr. 2007;15(3, Suppl 1):S7-S16.
9. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77-100.
10. Ardila R. Calidad de vida: una definición integradora. Rev Latinoamericana Psicol. 2003;35(2):161-164.
11. Matta M, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol. 2008;158:305-310.
12. Nienke R, Biermasz N, Van Thiel S, et al. Quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab. 2004;89(11):5369-5367.
13. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol. 1988;56:893-897.
14. Magán I, Sanz J, García-Vera MP. Psychometric properties of a Spanish version of the Beck anxiety inventory (BAI) in general population. Spanish J Psychol. 2008;11:626-640.
15. Bardhoshi G, Duncan K, Erford BT. Psychometric meta-analysis of the English version of the beck anxiety inventory. J Couns Dev. 2016;94:356-373.
16. Anagnostis P, Efstathiadou ZA, Charizopoulou M, et al. Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases? Endocrine. 2014;47(2):564-571.
17. Celik O, Kadioglu P. Quality of life in female patients with acromegaly. J Endocrinol Invest. 2013;36(6):412-416.
18. Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P. Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary. 2014;17(6):557-563.
19. Van der Klaaw A, Nienke KM, Roelfsema F, et al. Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol. 2008;69(5):775-784.
20. Solomon E, Brânisteau D, Dumbravă A, et al. Executive functioning and quality of life in acromegaly. Psychol Res Behav Manag. 2019;12(39):44.
21. Anagnostis P, Efstathiadou ZA, Charizopoulou M, et al. Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases? Endocrine. 2014;47(2):564-571.
22. Milian M, Honegger J, Gerlach C, Psaras T. Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors—a longitudinal study of 106 patients. Acta Neurochir (Wien). 2013;155(9):1637-1645.discussion 1645.
23. Vandeva S, Yaneva M, Natchev E, Elenkova A, Kalinov K, Zacharieva S. Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire. Endocrine. 2015;49(3):774-782.

24. Garduño-Pérez A, Zamarripa-Escobedo R, Vergara-López A, González-M G, Escudero-Lincona I. Análisis de la calidad de vida en pacientes con acromegalia en el Centro Médico Nacional 20 de Noviembre, ISSSTE. Rev Endocrinol Nutr. 2011;19(3):97-101.

25. Laws E, Ezzat S, Asa S, Rio L. Pituitary Disorders: Diagnosis and Management. Massachusetts: John Wiley & Sons. 2013;1:293-299.

26. Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C. Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life. Front Endocrinol (Lausanne). 2014;5:229.

How to cite this article: Ballesteros-Herrera D, Briseño-Hernández P, Pérez-Esparza R, Portocarrero-Ortiz LA. Differences in quality of life between genders in acromegaly. Endocrinol Diab Metab. 2021;4:e00229. https://doi.org/10.1002/edm2.229